MedTrace Logo

Therapeutic Effect of an Herbal Medicine on Anxiety

NCT01178632 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2010-08-10

No results posted yet for this study

Summary

Phase III, double blind, randomized study, controlled by Valeriana officinalis L for evaluating the efficacy of association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L. in generalized anxiety disorder. The treatment period will last four weeks and be followed by a post treatment visit.

Conditions

  • Anxiety Disorders

Interventions

DRUG

Passiflora

01 tablet Passiflora p.o., b.i.d.

DRUG

Valeriana officinalis

Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.

Sponsors & Collaborators

  • Millet Roux

    lead INDUSTRY

Principal Investigators

  • MARIA ELISABETE A MORAES, MD, PhD · CLINICAL PHARMACOLOGY UNIT - UNIFAC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-12-31
Completion
2012-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178632 on ClinicalTrials.gov